NewsBELTAS Attending
BELTAS Submission
BELTAS Submission
BELTAS Presents
BELTAS Presents
BELTAS in the News
Press Release
BELTAS, a contract research organisation (CRO), manages and monitors clinical studies in hospitals and clinics throughout New Zealand, Australia and Europe. The company also provides internationally accredited training and qualifications in Good Clinical Practice (GCP) for organisations considering or undertaking clinical trials. "We're thrilled at our placing in the top 30 fastest growing companies in New Zealand and eighth in our home base of Auckland," says Managing Director Gerard Dunne. "Our aim is to attract high quality medical research to New Zealand and Australia, for the benefit of patients, hospitals and clinical staff here. Both countries are ideal for clinical trials combining first world standards, responsiveness and a practical ethics and regulatory environment. "All our clinical staff are internationally accredited and in the clinical research field, quality is our lifeblood." In 2008, analyst estimates of the global market for CRO services ranged from US$18 billion to US$20 billion, with an annual growth rate of 10 to 15 percent. BELTAS, founded in 2003 by Dunne, and Helmine Verhoeven (now based in The Netherlands), posted an increase of 222% over the 2009 Fast 50 three-year period. BELTAS has been a New Zealand exporter from its first year of operation, using its internationally gained expertise to assist local biotechnology, drug, diagnostic and device companies to develop products within the Australasian region for the global market. Matt McKendry, Deloitte's Fast 50 leader, says BELTAS is one of several companies with a medical focus on this year's Fast 50 list. "BELTAS has carved out a niche focusing on attracting international medical research to Australasia from the USA and Europe and it is clearly doing a lot right, given the company's performance in the past three years." BELTAS staff are among founding members of the NZ Association of Clinical Research and members of NZBio. The company sponsors the NZ Organisation for Rare Disorders, for children and adults with rare genetic conditions. The Fast 50 is a Deloitte initiative which operates in more than 32 countries and territories around the world. It ranks businesses that choose to participate and is firmly established as a key barometer of New Zealand's emerging business market. Research ArticleGCPj Journal
Research NewsNZ Study shows benefits of daily texting
|
"VCs poured $7.2 billion -- 28 percent of all venture capital invested last year -- into the fields of biotechnology and medical devices." - Inc.com |
Auckland company BELTAS Clinical Research is a 2009 Deloitte Fast 50 winner after a period of strong growth.
Geography, and local knowledge, can be a huge factor when recruiting patients for clinical trials. Gerard Dunne of New Zealand-based CRO BELTAS raises …
A study in New Zealand demonstrated that providing motivational support through daily text messages to young cigarette smokers might help them quit smoking. 
